To the Editor: The regression of Kaposi's sarcoma in renal-graft recipients after switching from treatment with cyclosporine and mycophenolate mofetil to sirolimus, as reported by Stallone et al. (March 31 issue),1 is remarkable and confirms earlier observations.2,3 However, the immunohistochemical results in this study1 seem to be less convincing. The detection of Flk-1/KDR was reportedly performed on acetone-fixed kidney sections, but it is clearly stated that patients had no visceral involvement. Figure 2A, Figure 2B, and Figure 2C of the article do not seem to show greatly different vascular endothelial growth factor (VEGF) expression, certainly not in the range of . . .
No takes yet. Share an insight, caveat, or question.
Gutiérrez-Dalmau et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: